Preclinical discovery and development of nirmatrelvir/ritonavir combinational therapy for the treatment of COVID-19 and the lessons learned from SARS-COV-2 variants-Reference-Cited by-同舟云学术

Preclinical discovery and development of nirmatrelvir/ritonavir combinational therapy for the treatment of COVID-19 and the lessons learned from SARS-COV-2 variants

Published:2023-08-23 Issue:12 Volume:18 Page:1301-1311
ISSN:1746-0441
Container-title:Expert Opinion on Drug Discovery
language:en
Short-container-title:Expert Opinion on Drug Discovery

Author:

Pagliano Pasquale¹,Spera Annamaria¹^ORCID,Sellitto Carmine²,Scarpati Giuliana³,Folliero Veronica⁴,Piazza Ornella³,Franci Gianluigi⁴,Conti Valeria²,Ascione Tiziana⁵

Affiliation:

1. Department of Medicine, Surgery and Dentistry, “Scuola Medica Salernitana”, Unit of Infectious Diseases, University of Salerno, Baronissi, Italy

2. Department of Medicine, Surgery and Dentistry, “Scuola Medica Salernitana”, Unit of Pharmacology, University of Salerno, Baronissi, Italy

3. Department of Medicine, Surgery and Dentistry, “Scuola Medica Salernitana”, Unit of Anesthesiology, University of Salerno, Baronissi, Italy

4. Department of Medicine, Surgery and Dentistry “Scuola Medica Salernitana”, Unit of Microbiology, University of Salerno, Baronissi, Italy

5. Department of Medicine, Service of Infectious Diseases, Cardarelli Hospital, Naples, Italy

Publisher

Informa UK Limited

Subject

Drug Discovery

Link

https://www.tandfonline.com/doi/pdf/10.1080/17460441.2023.2248879

Reference60 articles.

1. Risk Factors Associated With Hospitalization and Death in COVID-19 Breakthrough Infections

2. New COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status — New York, May 3–July 25, 2021

3. Characteristics of viral pneumonia in the COVID-19 era: an update

4. Neurologic aspects of covid-19: a concise review;Brouwer MC;Infez Med,2020

5. Facing the New Covid-19 Reality